Liraglutide suppresses atrial electrophysiological changes

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• Dipeptidyl peptidase-4 (DPP-4) inhibitors are known to suppress atrial remodeling in canine models of atrial fibrillation (AF).
• DPP-4 inhibitors increase glucagon-like peptide-1 (GLP-1) levels, but the direct role of GLP-1 in suppressing atrial remodeling remains unclear.

Purpose of the Study:

• To investigate the effect of liraglutide, a GLP-1 analog, on atrial electrophysiological changes in a canine AF model.
• To determine if GLP-1 signaling is involved in the suppression of atrial remodeling.

Main Methods:

• A canine AF model was established using 3-week rapid atrial stimulation in beagle dogs.
• Dogs were divided into a liraglutide treatment group and a pacing control group.
• Atrial electrophysiological parameters including atrial effective refractory period (AERP), conduction velocity (CV), and AF inducibility were assessed weekly.

Main Results:

• While AERP shortening was similar between groups, liraglutide significantly increased CV compared to controls after 2 and 3 weeks (p=0.0339).
• AF inducibility was significantly suppressed in the liraglutide group (5±9%) compared to the pacing control group (73±5%; p=0.0262).
• Liraglutide demonstrated a significant suppression of AF inducibility and mitigated CV decrease.

Conclusions:

• Liraglutide, a GLP-1 analog, effectively suppressed atrial electrophysiological changes in a canine AF model.
• These findings suggest that GLP-1 signaling may be a key mechanism underlying the anti-atrial remodeling effects observed with DPP-4 inhibitors.